205 related articles for article (PubMed ID: 24926196)
1. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.
Samtani MN; Raghavan N; Novak G; Nandy P; Narayan VA
Neuropsychiatr Dis Treat; 2014; 10():929-52. PubMed ID: 24926196
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
3. Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.
Ito K; Hutmacher MM
J Alzheimers Dis; 2014; 40(4):967-79. PubMed ID: 24531162
[TBL] [Abstract][Full Text] [Related]
4. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.
Samtani MN; Farnum M; Lobanov V; Yang E; Raghavan N; Dibernardo A; Narayan V;
J Clin Pharmacol; 2012 May; 52(5):629-44. PubMed ID: 21659625
[TBL] [Abstract][Full Text] [Related]
5. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
[TBL] [Abstract][Full Text] [Related]
6. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T;
Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
[TBL] [Abstract][Full Text] [Related]
8. Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.
Samtani MN; Raghavan N; Shi Y; Novak G; Farnum M; Lobanov V; Schultz T; Yang E; DiBernardo A; Narayan VA;
Br J Clin Pharmacol; 2013 Jan; 75(1):146-61. PubMed ID: 22534009
[TBL] [Abstract][Full Text] [Related]
9. Informant characteristics are associated with the Clinical Dementia Rating Sum of Boxes scores in the Alzheimer's Disease patients participating in the National Alzheimer's Coordinating Center Uniform Data Set.
Vargas-Gonzalez JC; Chadha AS; Castro-Aldrete L; Ferretti MT; Tartaglia C
Res Sq; 2024 Mar; ():. PubMed ID: 38559129
[TBL] [Abstract][Full Text] [Related]
10. Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.
Peterson D; Munger C; Crowley J; Corcoran C; Cruchaga C; Goate AM; Norton MC; Green RC; Munger RG; Breitner JC; Welsh-Bohmer KA; Lyketsos C; Tschanz J; Kauwe JS;
Alzheimers Dement; 2014 May; 10(3):366-71. PubMed ID: 23727081
[TBL] [Abstract][Full Text] [Related]
11. Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer's Disease: Estimates from Real-World Data.
Chandler J; Done N; Desai U; Georgieva M; Gomez-Lievano A; Ye W; Zhao A; Eid D; Hilts A; Kirson N; Schilling T
J Prev Alzheimers Dis; 2024; 11(2):310-319. PubMed ID: 38374737
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
13. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
14. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
[TBL] [Abstract][Full Text] [Related]
15. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
[TBL] [Abstract][Full Text] [Related]
16. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
18. Elevations in Serum Dickkopf-1 and Disease Progression in Community-Dwelling Older Adults With Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease.
Tay L; Leung B; Yeo A; Chan M; Lim WS
Front Aging Neurosci; 2019; 11():278. PubMed ID: 31680933
[No Abstract] [Full Text] [Related]
19. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
Huang Y; Ito K; Billing CB; Anziano RJ;
Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
[TBL] [Abstract][Full Text] [Related]
20. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.
Chou YY; Leporé N; Avedissian C; Madsen SK; Parikshak N; Hua X; Shaw LM; Trojanowski JQ; Weiner MW; Toga AW; Thompson PM;
Neuroimage; 2009 Jun; 46(2):394-410. PubMed ID: 19236926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
